Results 81 to 90 of about 22,035 (254)

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.

Journal of Pharmaceutical and Biomedical Analysis, 2020
Therapeutic drug monitoring (TDM) is essential in the optimization of antiretroviral (ARV) treatments. In this work, we describe a new method for the simultaneous quantification of six molecules: the three novel ARV agents dolutegravir (DTG ...
Yi Zheng, R. Aboura, S. Boujaafar, Gabrielle Lui, D. Hirt, N. Bouazza, F. Foissac, J. Treluyer, S. Benaboud, I. Gana   +9 more
semanticscholar   +1 more source

Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice

HIV Medicine, 2021
We evaluated the virological response and resistance profile in combined antiretroviral therapy (cART)‐experienced HIV‐1‐infected patients starting a dual therapy with dolutegravir (DTG) and boosted darunavir (bDRV) for the first time.
D. Armenia, Y. Bouba, R. Gagliardini, L. Fabeni, V. Borghi, G. Berno, A. Vergori, S. Cicalini, C. Mussini, A. Antinori, F. Ceccherini‐Silberstein, C. Perno, M. Santoro   +12 more
semanticscholar   +1 more source

Synthesis of Sulfur Enriched Cyclohexenes via the Tungsten‐Promoted Dearomatization of a Phenyl Sulfone

European Journal of Organic Chemistry, Volume 29, Issue 9, 2 March 2026.
A method for synthesizing sulfur‐substituted cyclohexenes is reportedthat leverages the η2‐coordination of a phenyl sulfone to [WTp(NO)(PMe3)] (Tp = trispyrazolylborate). Three sequential protonation and nucleophilic additions to the bound arene, followed by oxidative decomplexation, affords functionalized cyclohexenes bearing sp3‐ and sulfur‐enriched ...
Daniel J. Siela, Matthew C. McGraw, Diane A. Dickie, W. Dean Harman   +3 more
wiley   +1 more source

Role of darunavir in the management of HIV infection

HIV/AIDS: Research and Palliative Care, 2009
R Monica Lascar, Paul BennThe Mortimer Market Centre, Camden PCT, London WC1E 6JBAbstract: There is an ongoing need for potent antiretroviral therapies to deal with the increasing pool of treatment-experienced patients with multiple drug resistance.
R Monica Lascar, Paul Benn
doaj  

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART [PDF]

, 2015
Peer reviewedPublisher ...
Baguley, Steve, Brawley, Daniela, Butt, Ambreen, Ismail, Muhammad A, Okpo, Emmanuel, Tonna, Ivan   +5 more
core  

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro [PDF]

, 2017
Treatment of HIV-infected patients coinfected with Mycobacterium tuberculosis is challenging due to drug-drug interactions (DDIs) between antiretrovirals (ARVs) and antituberculosis (anti-TB) drugs.
Khoo, Saye, Owen, Andrew, Roberts, Owain, Siccardi, Marco   +3 more
core   +1 more source

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Future Journal of Pharmaceutical Sciences, 2021
Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on 1st July ...
M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey   +2 more
semanticscholar   +1 more source

Influence of Serum Carbamazepine Concentration on the Anticoagulant Effect of Warfarin in a Pediatric Case: Effects of Carbamazepine Tapering and Discontinuation During Concomitant Sodium Valproate Therapy

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT This case demonstrates an inverse relationship between serum carbamazepine concentration and the prothrombin time–international normalized ratio (PT‐INR) adjusted for the warfarin dose. The concomitant use of sodium valproate further contributes to an unstable PT‐INR, emphasizing the importance of careful and continuous monitoring of ...
Yuki Shirayama, Yu Takasao, Toshiyuki Shinozaki, Masayuki Abiko, Kota Suzuki, Kosuke Doki   +5 more
wiley   +1 more source

Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance

mBio, 2018
Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1
Manabu Aoki, Debananda Das, Hironori Hayashi, Hiromi Aoki-Ogata, Yuki Takamatsu, Arun K. Ghosh, Hiroaki Mitsuya   +6 more
doaj   +1 more source